RxDoctor Payments Data

Alicia Wojchik

Adult Health · Chaska, MNNPI 1609845833

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Merck accounts for 92.7% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $8,827, 8.7 times the $1,015 reported in 2021. Among adult health clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,430in general payments, 2019–2025

Across 27 payments — averaging $534.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$13K
  • AstraZeneca$1K
  • Daiichi Sankyo Inc.$16
  • E.r. Squibb & Sons, L.L.C.$16

What the payments were for

  • Consulting fees$1,0157%
  • Speaking & faculty fees$7,07049%
  • Travel & lodging$6,03242%
  • Food & beverage$2972%
  • Education$160%

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck24$13,382
AstraZeneca1$1,015
Daiichi Sankyo Inc.1$16
E.r. Squibb & Sons, L.L.C.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,430 in reported general payments places this provider in the 95th percentile of 233 adult health providers in Minnesota.

See all adult health providers in Minnesota

Medicare billing

Part B allowed, 2024
$319,537
Medicare patients
147
Services billed
16,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide18$294,287
PomalystPomalidomide11$243,868
TagrissoOsimertinib Mesylate12$192,579
EliquisApixaban23$24,326
Tamoxifen Citrate38$1,405
Letrozole76$1,369
Hydroxyurea31$834
Dexamethasone26$647
Anastrozole21$509
Potassium Chloride35$482
Acyclovir22$415
Gabapentin38$387
Oxycodone Hcl20$333
Ondansetron OdtOndansetron23$318
Morphine Sulfate ErMorphine Sulfate12$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$16$243,86811 claims
AstraZenecaTagrisso$1,015$192,57912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 adult health providers in Minnesota.

Other adult health in Chaska

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →